John Marren, senior director, NOVAVAX
NOVAVAX, a Maryland-based business producing next-generation vaccines, has appointed John Marren as senior director for global risk and insurance management.
Marren joins with more than three decades’ experience in risk management. Starting as a loss prevention consultant with Factory Mutual Engineering Corporation, he then spent almost a decade at Marsh, where he was vice president.
He has significant experience managing captives, both with Geneva-based fragrance manufacturer Firmenich, and for chemical group Henkel of America, where he served as director of its Barbados-domiciled chemical industry group captive, Primex.
Until 2021, Marren has a senior director for global risk and insurance manager with biotherapy business CSL Behring, where he spent 14 years.
Novavax is currently preparing to submit applications for its protein-based COVID-19 vaccine to the US Food & Drug Administration (FDA) for emergency use authorisation. It has also applied for approval in several other countries.
John Marren, NOVAVAX, risk management, global risk, insurance management, Insurance, Reinsurance, North America, Factory Mutual Engineering Corporation